Risperidone: a review of efficacy studies in adolescents with schizophrenia.

Abstract

Risperidone has been approved by the Food and Drug Administration for the treatment of schizophrenia in the adolescent population. This new indication has been a result of data obtained from two pivotal double-blind trials with supplemental information from open-label and retrospective trials. This brief article provides an overview of risperidone's pharmacological profile followed by information on the double-blind trials that have resulted in the approval of risperidone for the treatment of adolescent schizophrenia. Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.